| News

RocketVax secures partners for coronavirus vaccine in Basel

17.06.2021

RocketVax has found cooperation partners for the development of its innovative coronavirus vaccine. The University Hospital of Basel, the University of Basel and the Swiss Tropical and Public Health Institute are providing funding, research infrastructure and staff resources.

biotechnology

The University Hospital of Basel (USB), the University of Basel and the Swiss Tropical and Public Health Institute (Swiss TPH) are entering into a research cooperation with RocketVax. All four are based in Basel. Founded a year ago, the startup is developing a next-generation vaccine against COVID-19. It reportedly induces a long-lasting immune response and works more effectively against mutations. “The Basel region offers the requisite expertise and innovative ideas for further developing the vaccine,” the USB explained in a press release. “The research partners are exploiting this potential to now open a ‘window of opportunity’.”

Through seed funding of 1 million Swiss francs, the USB is enabling the preclinical research work on the vaccine that has already begun to continue. The University of Basel and the Swiss TPH are contributing their research infrastructure and staff resources to the project. The Canton of Basel-Stadt is supporting the research cooperation with a further 1 million francs. According to the USB, Switzerland and other countries stand to benefit from a vaccine made in the Basel region. The first six-month project phase was backed by Innosuisse, through funding of 1.2 million francs.

The RocketVax vaccine uses coronavirus-based vectors. Different to first-generation vaccines that only target the spike protein, it is above all characterized by the fact that it activates multiple lines of immune system defense to combat the SARS-CoV-2 virus. The aim here is to provoke a much broader antibody reaction and to reduce risks connected with viral escape mechanisms. The designed genome lacks one essential virus element needed for replication, meaning it is not infectious.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Botanikind settles in Basel
Basel Area Business & Innovation, Innovation, Invest

Botanikind settles in Basel

The internationally active Swiss company Botanikind has settled in Basel and established Botanikind AG there. It provides natural ingredients for...

Read More
Kinarus secures capital commitment of 57 million Swiss francs
Basel Area Business & Innovation, Innovation, Invest

Kinarus secures capital commitment of 57 million Swiss francs

The biopharmaceutical company Kinarus has signed a capital commitment of up to 57 million Swiss francs with the investment group...

Read More
Biotech startups from the Basel Area confirm leading position
Basel Area Business & Innovation, Innovation, Invest, Switzerland Innovation Park

Biotech startups from the Basel Area confirm leading position

As part of the Top 100 Swiss Startup Awards 2021, the most promising startups in Switzerland are honored. These also...

Read More
T3 Pharma wins Swiss Economic Award
Basel Area Business & Innovation, Innovation, Invest

T3 Pharma wins Swiss Economic Award

T3 Pharma has won the Swiss Economic Award 2021. Switzerland’s most prestigious young entrepreneur prize is awarded by the Swiss...

Read More
Worg selects Basel Area for European headquarters
Basel Area Business & Innovation, Innovation, Invest, Switzerland Innovation Park

Worg selects Basel Area for European headquarters

Worg Pharmaceuticals has opted to establish its European headquarters at the site Allschwil of the Switzerland Innovation Park Basel Area....

Read More
ten23 health settles in Basel
Basel Area Business & Innovation, Innovation, Invest

ten23 health settles in Basel

The life sciences cluster Rosental Mitte located in Basel is home to a new, globally active company called ten23 health....

Read More
1 2 3 48

Do you have a question? We'd like to hear from you.